Clomid or Gonadotropins

When considering treatment for-non-ovulating women with normal pituitary hormones, a decision must be made about which type of drug to use to enhance the chances of success: oral agents like CLOMID® (clomiphene citrate) or FEMARA® (letrozole) or injectables represented by a variety of gonadotropins, MENOPUR® (menotropins for injection), GONAL-F® (follitropin alfa for injection), BRAVELLE® (urofollitropin), and FOLLISTIM® (follitropin beta injection). …

Does Fertility Treatment Have Long Term Side Effects?

A new study published in the Canadian Medical Association journal reports a greater risk of heart failure and stroke in women who did not become pregnant after undergoing gonadotropin-based fertility treatment. The study looked at over 28,000 women, who underwent fertility treatment with injectable medications between 1993 and 2011 in Ontario, Canada.  Women who did not conceive with treatment had …

Conceiving with endometriosis-do you need IVF?

There is a very good review of the effects of endometriosis on fertility and the rationale for various types of treatment including surgery, injectable medications with IUI and eventually IVF.

Endometriosis creates an inflammatory environment in the pelvis and reproductive system, leading to the development of adhesions (scar tissues) and endometriomas (cysts known as chocolate cysts), which cause chronic pelvic …

New study finds no link between fertility drugs and ovarian cancer

Despite lingering concerns that fertility drugs increase the risk of ovarian cancer, a new case-control study suggests they don’t contribute any added risk.

“Women who need to use fertility drugs to get pregnant should not worry about using these fertility drugs,” said lead author Dr. Albert Asante of the Mayo Clinic in Rochester, Minnesota.

Research on fertility drugs and cancer …

Is IVF the correct first treament for unexplained infertility?

This is one of a series of news items from abstracts of studies presented at the Annual Meeting of the American Society for Reproductive Medicine as complied by Dr. David Meldrum, Scientific Director of Reproductive Partners. We appreciate the enormous amount of work it takes to compile and comment on these abstracts.


 Women over 38 with at least